Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Change in Accured Expenses (2016 - 2026)

Cytosorbents filings provide 15 years of Change in Accured Expenses readings, the most recent being -$539000.0 for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 139.69% to -$539000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$706000.0, a 60.95% increase, with the full-year FY2025 number at -$706000.0, up 60.95% from a year prior.
  • Change in Accured Expenses hit -$539000.0 in Q4 2025 for Cytosorbents, down from $193000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.1 million in Q4 2021 to a low of -$1.3 million in Q1 2024.
  • Median Change in Accured Expenses over the past 5 years was -$272603.0 (2022), compared with a mean of -$86440.1.
  • Biggest five-year swings in Change in Accured Expenses: plummeted 490.9% in 2022 and later skyrocketed 371.1% in 2023.
  • Cytosorbents' Change in Accured Expenses stood at $2.1 million in 2021, then crashed by 109.71% to -$206441.0 in 2022, then soared by 371.1% to $559666.0 in 2023, then skyrocketed by 142.64% to $1.4 million in 2024, then tumbled by 139.69% to -$539000.0 in 2025.
  • The last three reported values for Change in Accured Expenses were -$539000.0 (Q4 2025), $193000.0 (Q3 2025), and $7282.0 (Q2 2025) per Business Quant data.